Scientists test Single-Dose nasal spray to shield newborns from whooping cough
NCT ID NCT01188512
Summary
This early-stage study tested the safety and immune response of a new, genetically modified whooping cough vaccine given as a single nasal spray. It involved 48 healthy adult male volunteers to see if the vaccine was well-tolerated and triggered an immune reaction. The ultimate goal is to develop a vaccine that could protect very young infants, who are most vulnerable, before they start their regular vaccination schedule.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERTUSSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karolinska University Hospital
Solna, 171 76, Sweden
Conditions
Explore the condition pages connected to this study.